Resistant hypertension

Canadian Journal of Cardiology

Volumn 25, Issue 5, 2009, Pages 315-317

  Tobe, Sheldon W ^a   Lewanczuk, Richard ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Capital Health Edmonton   (Canada)

Author keywords

Hypertension; Resistant hypertension

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; HYDRALAZINE; METHYLDOPA; MINOXIDIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DISEASE CONTROL; HUMAN; HYPERTENSION; LABORATORY TEST; MEDICAL SPECIALIST; PATIENT REFERRAL; PHYSICAL EXAMINATION; SIDE EFFECT; WATER RETENTION;

EID: 65949120711     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70496-9     Document Type: Article

References (22)

1. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 205;18:1422-8.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-72.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
4. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, RUSH University Hypertension Service. Resistant hypertension revisited: A comparison of two university-based cohorts. Am J Hypertens 2005;18:619-26.
5. Epstein M. Resistant hypertension: Prevalence and evolving concepts. J Clin Hypertens 2007;9:2-6.
6. Pickering TG. Arterial stiffness as a cause of resistant hypertension? J Clin Hypertens 2007;9:390-5.
7. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271-7.
8. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. True resistant hypertension: Is it possible to be recognized in the office? Am J Hypertens 2005;18:1534-40.
9. Park J, Campese V. Clinical characteristics of resistant hypertension: The importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens 2007;9:7-12.
10. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404.
11. Black HR, Elliott WJ, Grandits G, et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens 2005;23:1099-106.
12. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
13. van Jaarsveld BC, Krijnen P, Derkx FH, et al. Resistance to antihypertensive medication as predictor of renal artery stenosis: Comparison of two drug regimens. J Human Hypertens 2001;15:669-76.
14. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6.
15. Duprez DA. Aldosterone and the vasculature: Mechanisms mediating resistant hypertension. J Clin Hypertens 2007;9:13-8.
16. Padwal R, Campbell NR, Feldman RD, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009;25:279-86.
17. White WB. Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. J Clin Hypertens 2007;9:25-30.
18. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991;151:1786-92.
19. Prisant LM, Dillard TA, Blanchard AR. Obstructive sleep apnea syndrome. J Clin Hypertens 2006;8:746-50.
20. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens 2007;9:19-24.
21. de Castro MS, Fuchs FD, Santos MC, et al. Pharmaceutical care program for patients with uncontrolled hypertension. Report of a double-blind clinical trial with ambulatory blood pressure monitoring. Am J Hypertens 2006;19:528-33.
22. Redon J. Managing resistant hypertension: Not just a question of numbers. Am J Hypertens 2005;18:1541-2.